{
  "claim_id": "claim_007",
  "claim": "Recombinant HA antigens produced using BEVS have been shown to induce significantly higher levels of broadly cross-reactive antibodies against highly conserved regions of HA compared with egg-derived vaccines.",
  "document": "FlublokPI",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": false,
    "additional_count": 0
  },
  "completeness_stats": {
    "existing_evidence": 2,
    "new_evidence_found": 0,
    "total_evidence": 2
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "5. Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA. 2007 Vol. 297, pp. 1577-1582.",
      "relevance_explanation": "This reference is cited in the context of Flublok's clinical studies and specifically addresses the immunogenicity of a baculovirus-expressed (BEVS-produced) hemagglutinin vaccine, which directly relates to the claim about recombinant HA antigens produced using BEVS."
    },
    {
      "id": 2,
      "quote": "3. Keitel WA, Treanor JJ, El Sahly HM, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among persons \u226565 years old. Vaccine 2009 Vol. 28, pp. 379\u2013385.",
      "relevance_explanation": "This reference is cited as a comparative study of the immunogenicity of recombinant HA (produced using BEVS) versus egg-derived trivalent inactivated vaccines, which is directly relevant to the claim about higher levels of broadly cross-reactive antibodies."
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}